Search company, investor...
iPierian company logo


Founded Year



Acquired | Acquired

Total Raised




About iPierian

iPierian is a biotechnology company developing therapies for neurodegenerative disease, specifically focused on discovering monoclonal antibodies against targets of the Tau protein for treatment of Alzheimer's disease and other tauopathies (e.g. progressive supranuclear palsy, frontotemporal dementia). The company's lead antibody, IPN007, represents a new approach to Alzheimer's by targeting a novel form of secreted Tau protein that is differentially regulated in Alzheimer's disease patients, to slow the spread of Tau throughout the brain and therefore inhibit the associated disease progression. iPierian's monoclonal antibody program for Tau is based on novel Tau discoveries made using the company's proprietary induced pluripotent stem cell (iPSC) technology.

Headquarters Location

951 Gateway Boulevard

South San Francisco, California, 94080,

United States


Missing: iPierian's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: iPierian's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing iPierian

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

iPierian is included in 1 Expert Collection, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).

iPierian Patents

iPierian has filed 16 patents.

The 3 most popular patent topics include:

  • Cognitive disorders
  • Dementia
  • Gene expression
patents chart

Application Date

Grant Date


Related Topics




Monoclonal antibodies, Proteins, Molecular biology, Small nuclear RNA, Immune system


Application Date


Grant Date



Related Topics

Monoclonal antibodies, Proteins, Molecular biology, Small nuclear RNA, Immune system



Latest iPierian News

Bristol Flips Remnants of Adnexus, iPierian to Roche, Biogen For $470M

Apr 13, 2017

XconomyNew York —  Priorities change over time for drugmakers, as evidenced today by Bristol-Myers Squibb. The company announced two separate deals for experimental drugs that no longer fit its strategy—both of which were remnants of old acquisitions and a past plan to zero in on genetic diseases. In one deal, Bristol (NYSE: BMY ) has sent Biogen (NASDAQ: BIIB ), of Cambridge, MA, an experimental drug (BMS-986168) for a neurological disease called progressive supranuclear palsy (PSP). Bristol gets $300 million up front from Biogen in this deal, with another $410 million in possible future payments if the drug progresses. PSP is a devastating, rare neurodegenerative disease that causes problems walking and thinking and leads to other significant health problems, like pneumonia. There are no effective treatments. This attracted Bristol, which acquired the drug when it bought South San Francisco-based iPerian for $175 million up front in 2014 . Bristol’s R&D chief Francis Cuss noted in a statement at the time the company was zeroing in on “genetically defined diseases” where patients had limited options. iPierian’s drug is designed to stop a form of the protein Tau called “eTau” from spreading from neuron to neuron in the brain. In acquiring the PSP drug, Biogen is also now on the hook for any remaining payments due to the stockholders of iPierian, which include Kleiner Perkins Caufield & Byers, MPM Capital, GV (formerly known as Google Ventures), and SR One. Bristol’s latest annual report, filed in February , shows the company owed another $554 million in contingent payments tied to the iPierian deal. The drug just began Phase 2 testing, with results expected in 2019, according to . (Prior to the acquisition, meanwhile, iPierian split itself in two—the rest of the company became True North Therapeutics , which remains independent.) Another drug Bristol was developing under its genetic disease plan was a therapy acquired in a 2007 buyout of Adnexus Therapeutics. Bristol paid $415 million for Adnexus, of Waltham, MA, , a company that had been developing biologic drugs derived from the protein fibronectin. One experimental drug to come from that work was BMS-986089, a drug for Duchenne muscular dystrophy, a progressive muscle disease that puts patients in wheelchairs by their teens and often kills them at a young age from heart and lung complications. Swiss pharma giant Roche is buying BMS-986089, a drug that blocks myostatin, a protein implicated in muscle growth, for $170 million up front. BMS-986089 also recently began mid-stage testing, according to , and Bristol is one of several companies—among them Pfizer, Regeneron Pharmaceuticals, and Novartis—developing myostatin-blocking drugs to treat Duchenne and other diseases. Bristol could get another $205 million in downstream payments and royalties if the drug ever reaches the market. Combined, the PSP and Duchenne drugs were the only two in Bristol’s pipeline targeting genetic diseases. The drugmaker is now far more focused on cancer, where it is one of the leaders in immunotherapy, and immunology, where it has been building up a pipeline of drugs targeting fibrosis and the liver disease nonalcoholic steatohepatitis, among other disorders. Bristol’s most recent buyouts, among them Padlock Therapeutics , Flexus Biosciences , Nitto Denko, and Cormorant Pharmaceuticals , all fit within these areas. “Licensing these assets to Biogen and Roche will enable Bristol-Myers Squibb to prioritize the other promising opportunities for asset development that have advanced across our diversified portfolio,” said Mike Burgess, Bristol’s head of cardiovascular, fibrosis and immunoscience. Ben Fidler is Xconomy's Deputy Biotechnology Editor. You can e-mail him at Follow @benthefidler

iPierian Frequently Asked Questions (FAQ)

  • When was iPierian founded?

    iPierian was founded in 2007.

  • Where is iPierian's headquarters?

    iPierian's headquarters is located at 951 Gateway Boulevard, South San Francisco.

  • What is iPierian's latest funding round?

    iPierian's latest funding round is Acquired.

  • How much did iPierian raise?

    iPierian raised a total of $95.67M.

  • Who are the investors of iPierian?

    Investors of iPierian include Bristol-Myers Squibb, Highland Capital Partners, FinTech Global, MPM Capital, Kleiner Perkins Caufield & Byers and 10 more.

  • Who are iPierian's competitors?

    Competitors of iPierian include Arena Pharmaceuticals, Evotec SE, OcuNexus Therapeutics, Integral Molecular, Stemina Biomarker Discovery, Esperance Pharmaceuticals, Intarcia Therapeutics, CoImmune, Hydra Biosciences, TxCell and 83 more.

Compare iPierian to Competitors

Intarcia Therapeutics

Intarcia Therapeutics is a biopharmaceutical company based in Boston, Massachusetts. Intarcia is engaged in the development of a pipeline of products for the proprietary Medici Drug Delivery System comprised of three technologies: A stabilization technology that allows for proteins, peptides, antibody fragments, and other highly potent small molecules to be stabilized at or above human body temperatures, a matchstick-sized osmotic mini-pump that is placed under the dermal layer of skin to deliver a continuous and consistent flow of medication, and a placement technology including proprietary tools designed to provide an optimal user experience.


Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.

NeuroMolecular Pharmaceuticals

NeuroMolecular Pharmaceuticals is developing and commercializing superior neuroprotective medicines for the treatment of central nervous system (CNS) disorders. The Company has built a robust pipeline of neuropsychiatric products based upon its scientists' unique understanding of glutamate's central role in mediating CNS disorders. NeuroMolecular is rapidly advancing its next-generation medicines into clinical studies, with preclinical programs underway in depression, pain, Alzheimer's disease, Parkinson's disease, multiple sclerosis and epilepsy. NeuroMolecular is initially focusing on the development of superior derivatives and dosage formulations of memantine, a drug recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer's disease.

CoImmune Logo

CoImmune, fka Argos Therapeutics, is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. Using biological components from each patient, the company's immunotherapies employ the patient's dendritic cells to activate an immune response specific to the patient's disease.


JADO aims to become the leader in the emerging field of Raft intervention therapeutics, through the development of pharmaceutical products with potential for treating a range of human diseases. RAFTs are sub-compartments of cell membranes that play an integral role in key biological pathways. Using its drug development platform, called Raft Intervention Technology, JADO is exploiting new insights and understanding of cell membrane chemistry and organization that aims to enable us to address difficult to treat diseases, such as allergies (atopic dermatitis, asthma), viral and bacterial infections, cancer, neurodegenerative diseases (Alzheimer's) and metabolic illnesses (diabetes, lipid storage diseases).

Esperance Pharmaceuticals

Esperance Pharmaceuticals develops targeted anticancer drugs that selectively kill cancer cells without harming normal cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.